CYP1A1, CYP3A5 and CYP3A7 polymorphisms and testicular cancer susceptibility

International Journal of Andrology

Volumn 34, Issue 1, 2011, Pages 77-83

  Kristiansen, W ^a   Haugen, T B ^a   Witczak, O ^a   Andersen, J M ^a   Fossa S D ^b,c   Aschim, E L ^a  

^a OSLO METROPOLITAN UNIVERSITY   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

CYP450; Polymorphisms; Steroid hormone metabolism; Testicular cancer

Indexed keywords

CYTOCHROME P450 1A1; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7;

ARTICLE; CANCER SUSCEPTIBILITY; DNA POLYMORPHISM; GENOTYPE; HISTOLOGY; HUMAN; PRIORITY JOURNAL; TESTIS CANCER;

ALLELES; ARYL HYDROCARBON HYDROXYLASES; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP3A; GENETIC PREDISPOSITION TO DISEASE; GONADAL STEROID HORMONES; HUMANS; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; NORWAY; POLYMORPHISM, SINGLE NUCLEOTIDE; SEMINOMA; TESTICULAR NEOPLASMS;

EID: 78651283616     PISSN: 01056263     EISSN: 13652605     Source Type: Journal    
DOI: 10.1111/j.1365-2605.2010.01057.x     Document Type: Article

References (31)

1. Altman DG. (1991) Practical Statistics for Medical Research. Chapman and Hall, London.
2. Doherty JA, Weiss NS, Freeman RJ, Dightman DA, Thornton PJ, Houck JR, Voigt LF, Rossing MA, Schwartz SM & Chen C. (2005) Genetic factors in catechol estrogen metabolism in relation to the risk of endometrial cancer. Cancer Epidemiol Biomarkers Prev 14, 357-366.
3. Dong C, Lönnstedt I & Hemminki K. (2001) Familial testicular cancer and second primary cancers in testicular cancer patients by histological type. Eur J Cancer 37, 1878-1885.
4. Esinler I, Aktas D, Alikasifoglu M, Tuncbilek E & Ayhan A. (2006) Cyp1a1 gene polymorphism and risk of endometrial hyperplasia and endometrial carcinoma. Int J Gynecol Cancer 16, 1407-1411.
5. Ferlin A, Ganz F, Pengo M, Selice R, Frigo AC & Foresta C. (2010) Association of testicular germ cell tumour with polymorphisms in estrogen receptor and steroid metabolism genes. Endocr Relat Cancer 17, 17-25.
6. Figueroa J, Sakoda L, Graubard B, Chanock S, Rubertone M, Erickson R & McGlynn K. (2008) Genetic variation in hormone metabolizing genes and risk of testicular germ cell tumors. Cancer Causes Control 19, 917-929.
7. Fossa SD, Dahl AA & Loge JH. (2003) Fatigue, anxiety, and depression in long-term survivors of testicular cancer. J Clin Oncol 21, 1249-1254.
8. Gibson GG, Plant NJ, Swales KE, Ayrton A & El-Sankary W. (2002) Receptor-dependent transcriptional activation of cytochrome p4503a genes: induction mechanisms, species differences and interindividual variation in man. Xenobiotica 32, 165-206.
9. Guengerich FP. (1989) Polymorphism of cytochrome p-450 in humans. Trends Pharmacol Sci 10, 107-109.
10. Hanna IH, Dawling S, Roodi N, Guengerich FP & Parl FF. (2000) Cytochrome p450 1b1 (cyp1b1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res 60, 3440-3444.
11. Hefler LA, Tempfer CB, Grimm C, Lebrecht A, Ulbrich E, Heinze G et al. (2004) Estrogen-metabolizing gene polymorphisms in the assessment of breast carcinoma risk and fibroadenoma risk in caucasian women. Cancer 101, 264-269.
12. Heimdal K & Fosså SD. (1994) Genetic factors in malignant germ-cell tumors. World J Urol 12, 178-181.
13. Holl K, Lundin E, Surcel H-M, Grankvist K, Koskela P, Dillner J et al. (2009) Endogenous steroid hormone levels in early pregnancy and risk of testicular cancer in the offspring: a nested case-referent study. Int J Cancer 124, 2923-2928.
14. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K et al. (2001) The genetic determinants of the cyp3a5 polymorphism. Pharmacogenetics 11, 773-779.
15. Huyghe E, Matsuda T & Thonneau P. (2003) Increasing incidence of testicular cancer worldwide: a review. J Urol 170, 5-11.
16. Jacobsen R, Moller H, Thoresen SO, Pukkala E, Kjaer SK & Johansen C. (2006) Trends in testicular cancer incidence in the Nordic countries, focusing on the recent decrease in Denmark. Int J Androl 29, 199-204.
17. Kerlan V, Dreano Y, Bercovici JP, Beaune PH, Floch HH & Berthou F. (1992) Nature of cytochromes p450 involved in the 2-/4-hydroxylations of estradiol in human liver microsomes. Biochem Pharmacol 44, 1745-1756.
18. Kitada M, Kamataki T, Itahashi K, Rikihisa T & Kanakubo Y. (1987) P-450 HFLa, a form of cytochrome p-450 purified from human fetal livers, is the 16 alpha-hydroxylase of dehydroepiandrosterone 3-sulfate. J Biol Chem 262, 13534-13537.
19. Lakhani NJ, Sarkar MA, Venitz J & Figg WD. (2003) 2-methoxyestradiol, a promising anticancer agent. Pharmacotherapy 23, 165-172.
20. Landi MT, Bertazzi PA, Shields PG, Clark G, Lucier GW, Garte SJ, Cosma G & Caporaso NE. (1994) Association between cyp1a1 genotype, mRNA expression and enzymatic activity in humans. Pharmacogenetics 4, 242-246.
21. Lee AJ, Cai MX, Thomas PE, Conney AH & Zhu BT. (2003) Characterization of the oxidative metabolites of 17β-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology 144, 3382-3398.
22. Liehr JG. (2000) Is estradiol a genotoxic mutagenic carcinogen? Endocr Rev 21, 40-54.
23. Malm G, Haugen TB, Henrichsen T, Bjorsvik C, Grotmol T, Saether T et al. (2004) Reproductive function during summer and winter in Norwegian men living north and south of the Arctic Circle. J Clin Endocrinol Metab 89, 4397-4402.
24. Rajpert-De Meyts E. (2006) Developmental model for the pathogenesis of testicular carcinoma in situ: genetic and environmental aspects. Hum Reprod Update 12, 303-323.
25. Richiardi L, Bellocco R, Adami H-O, Torrang A, Barlow L, Hakulinen T et al. (2004) Testicular cancer incidence in eight northern European countries: secular and recent trends. Cancer Epidemiol Biomarkers Prev 13, 2157-2166.
26. Rodríguez-Antona C, Jande M, Rane A & Ingelman-Sundberg M. (2005) Identification and phenotype characterization of two cyp3a haplotypes causing different enzymatic capacity in fetal livers. Clin Pharmacol Ther 77, 259-270.
27. Sharpe RM & Skakkebaek NE. (1993) Are oestrogens involved in falling sperm counts and disorders of the male reproductive tract? Lancet 341, 1392-1396.
28. Sonneveld DJ, Sleijfer DT, Schraffordt Koops H, Sijmons RH, van der Graaf WTA, Sluiter WJ & Hoekstra HJ. (1999) Familial testicular cancer in a single-centre population. Eur J Cancer 35, 1368-1373.
29. Starr JR, Chen C, Doody DR, Hsu L, Ricks S, Weiss NS & Schwartz SM. (2005) Risk of testicular germ cell cancer in relation to variation in maternal and offspring cytochrome p450 genes involved in catechol estrogen metabolism. Cancer Epidemiol Biomarkers Prev 14, 2183-2190.
30. Wojnowski L. (2004) Genetics of the variable expression of cyp3a in humans. Ther Drug Monit 26, 192-199.
31. Wrighton SA, Brian WR, Sari MA, Iwasaki M, Guengerich FP, Raucy JL, Molowa DT & Vandenbranden M. (1990) Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol 38, 207-213.